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Evaluating the effect of a herb on the control of blood 
glucose and insulin-resistance in patients with advanced 
type 2 diabetes (a double-blind clinical trial) 
 
Abstract 
Background: Different benefits of various herbal medicines in decreasing blood sugar 
have been reported in different clinical trials so far. Considering the growing tendency 
toward these combinations and the booming market, inappropriate advice is growing 
accordingly. Hence, it is necessary to evaluate the effects and possible complications of 
such combinations on health status and blood glucose control. 
Methods: Two 38-subject groups were formed and a 12-week treatment program was 
administered for both groups. The inclusion criteria were failure to control blood glucose 
with two oral medicines, unwillingness to inject insulin. The medicine was prepared in 
capsules by Booali Company. Each capsule weighed 750 mg and contained nettle leaf 20% 
(w/w), berry leaf 10% (w/w), onion and garlic 20% (w/w), fenugreek seed 20% (w/w), 
walnut leaf 20% (w/w), and cinnamon bark 10% (w/w) all in powder. 
Results: At the beginning of the study, there was no significant difference between the 
subjects regarding the evaluated parameters, but after the intervention, the level of glucose 
was significantly lower in fasting (P=0.0001) and 2-hour postprandial (P=0.002) levels. 
The level of glycated hemoglobin A1c (HbA1c) (P=0.0001) also decreased from 
0.33±9.72 % to 0.20±8.39 %. Finally, the level of insulin resistance reduced from 1.9±4.1 
to 1.4±2.6 (P=0.001) after consuming herbal medicine. 
Conclusion: According to the results of the current study, the herbal combination was 
effective in controlling blood sugar, and considering the reduction of HbA1c by 1.31 %, it 
seems that the herbal combination is an effective medicine to treat diabetes. 
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Type 2 diabetes is one of the global public health concerns in the 21st century; both 
the developed and the developing countries are experiencing increasing rates of diabetes 
(1). Indeed, the prevalence and incidence of diabetes is still increasing constantly 
indicating a global diabetes epidemic (2). Currently, there are more than 150 million 
people with diabetes worldwide and it is predicted that the number increases to 366 million 
(constituting 4.4% of the world population) by 2030 (3). Diabetes is now a main cause of 
disability and hospitalization of patients and imposes a significant financial burden to the 
community. In India, 92 million USD is spent to treat patients with diabetes every year (4). 
In the first step, diabetes is treated by an oral antidiabetic drug (OAD); but with further 
development of the disease, the patient needs one or more antidiabetic drugs, in addition to 
the first prescribed agent (5). Before the discovery of insulin and invention of chemical 
drugs, physicians used herbal medicines to control diabetes. 
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Considering the high prevalence of diabetes and the 
concerns over the consequences of its complications, a wide 
range of complementary and alternative medicines (CAMs) 
with different effectiveness is used to control diabetes. 
Patients with diabetes show interest in using complementary 
and alternative medicine to control their blood sugar 1.6 
times more than their non-diabetic counterparts (6). 
Accordingly, 2-3.6 million Americans rely on 
complementary and alternative medicines to treat their 
diabetes (7). Reasons such as complicated common 
therapeutic regimens, hypoglycemia, personal beliefs, and 
side effects of drugs have decreased the patients’ compliance 
with common treatments and encouraged them to use 
complementary treatments (7). The tendency toward CAMs 
to treat diabetes has increased considerably from 30% to 
57% (8). In 2013, the estimation of spending on 
complementary and integrative medicine (CIM) in the USA 
reached 34 billion USD (9).  
The efficiency and benefits of more than 1200 herbal 
medicines in reducing blood sugar and diabetes 
complications have been reported so far (6). Considering the 
daily increase of interest in using such combinations and the 
booming market, inappropriate advice is growing in parallel. 
Hence, more meticulous studies should be conducted on the 
effectiveness and possible complications of such 
combinations on health status and control of blood sugar. 
Therefore, the current study aimed to evaluate the effect of a 
herbal medicine capsule on the control of blood glucose and 
insulin resistance. This capsule contained Urtica Dioica leaf, 
Morus Alba leaf, Allium sativum powder, Trigonella 
foenum-graecum seeds, Juglans regia leaf, and 
Cinnamomum zeylanicum bark. This drug combination is a 
capsule with a manufacturing license from the Iranian 
Ministry of Health Food and Drug Administration (License 
number: 026-89-S-T). Many studies have been conducted on 
some of the components of this drug, but so far no clinical 
trial study has been performed on the entire drug 
combination. A number of studies are as follows: 
Rajarajeswari et al. indicated that the aqueous extract of 
Fenugreek has significantly greater anti-diabetic effects as 
compared with the alcoholic extract (10, 11). Compound GІІ 
in Fenugreek can reduce the blood glucose and hemoglobin 
glycosylated levels while elevating the insulin level (12). 
According to Divbandand. K et al., oral administration of 
aqueous extract of Juglans Regia leaf at 400 mg/kg for 4 
weeks significantly reduced the blood glucose level in 
diabetic rats (P=0.009) (13). Shihabudeen M. S et al. 
revealed that the administration of alcoholic extract of 
Cinnamomum Zeylanicum bark in rats fed with sucrose and 
maltose led to inhibition of α-glucosidase and could stop 
post-prandial hyperglycemia. They believed that 
Cinnamomum Zeylanicum extract, in a reversible process, 
controls the hyperglycemia induced by sucrose and maltose 
after meal through inhibiting α-glucosidase enzyme (14). As 
Gholipour et al. presented in their study about the effect of 
Urtica Dioica leaf on diabetes management, the 
administration of Urtica Dioica leaf before induction of 
diabetes in rats increased the production of β-cells in 
Langerhans islets and decreased the concentration of blood 
glucose in diabetic rats by 60% (15). 
Regarding the growth in the prevalence of this disease 
and the increased use of herbal drugs and lack of knowledge 
about the effect of this herbal compound on diabetes, this 
study examined the level of blood glucose in diabetic 
patients in association with this herbal medicine. 
 
 
Methods  
Study Project: The current double-blind clinical trial was 
conducted on 76 patients with diabetes in two groups of case 
and control (placebo) in Shahid Beheshti Hospital, Qom, 
Iran, from 2014 to 2015. Figure 1 reveals the flowchart of 
the study. 
Study Population: Since the mentioned herbal combination 
had not been used in any other human studies for controlling 
diabetes, the combination was not used in the initial and 
standard treatments of diabetes in the current study. Also, as 
the study did not aim to deprive patients with diabetes from 
standard treatments, patients with no other therapeutic 
choices constituted the study population. Hence, the 
population was selected from patients who had completed 
the treatment course of two OADs, but due to inefficiency of 
OADs, they were candidates for starting insulin and based on 
some personal reasons refused insulin injection, despite the 
emphasis of their physicians.  
Inclusion and exclusion criteria: The inclusion criteria 
were: having type 2 diabetes within the age range of 25-70 
years, FBS > 130 mg/dL, and 2hppBG >180 mg/dL. The 
patients should have received two OADs and insulin 
injection, but were not willing to be injected. On the other 
hand, the exclusion criteria were: having cardiovascular, 
renal, and liver diseases, pregnancy, breastfeeding and history of 
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allergy to herbal products, having diseases with increased 
risk of allergy such as asthma and atopy, allergy to milk, lactose 
intolerance, and participation in another clinical trial.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The Study Flowchart 
 
Sampling: To determine the sample size in the current 
study, the sample size formula was used in two populations 
based on a previous study (16). Accordingly, the minimum 
sample size for each group was determined as 31, and based 
on estimating 15% attrition, eventually 38 subjects were 
assigned into each group. 
Random Sampling: To select the subjects randomly, a box 
with 76 numbered cards (from 1 to 76) was prepared and the 
subjects included in the study took a card and referred to the 
project collaborator pharmacy. Based on the card number, a 
box of medicine was given to the subject; half of the boxes 
contained the medicine and the rest were placebo.  
Requirements: Both medicine and placebo boxes were 
prepared by the same company with similar packages and 
boxes for all subjects. Half of the boxes contained the 
medicine and the rest were placebo, which were codified by 
a person not involved in the study by giving a number to 
each box. After enrolment of the subject into the study, they 
were given a number, and based on that the project 
collaborator pharmacy gave them a box with the same 
number. The subject was followed-up until the end of the 
study based on that number. At the end of the study, the 
subjects were divided into the case and control groups based 
on their numbers. 
Interventions 
Medicine: The medicine was prepared in capsules by Booali 
Company. Each capsule weighed 750 mg and contained of 
nettle leaf 20% (w/w), berry leaf 10% (w/w), onion and 
garlic 20% (w/w), fenugreek seed 20% (w/w), walnut leaf 
20% (w/w), and cinnamon bark 10% (w/w) all in powder.  
Placebo: The placebo was also prepared by the same 
company which manufactured the medicine in similar packages; 
each capsule contained micro-crystalline cellulose 50% 
(Avesil) and bran 50%. The shape, weight, taste, and color of 
the placebo capsule were similar to those of the medicine.  
The study period and grouping: The study was conducted 
in a 12-week period and the case group was under the 
treatment with an herbal medicine (with a determined 
combination certified by the Iranian Ministry of Health and 
Medical Education), three times a day, each time one capsule 
in addition to the previous drugs. Similarly, the placebo 
group also received placebo three times a day, each time one 
capsule in addition to the previous drugs. 
Outcomes: The morning fasting blood samples in the 
current study were taken from antecubital veins. Then, the 
samples were centrifuged and the serum was collected. 
Glucose, urea, creatinine, triglycerides, cholesterol, 
Aspartate Transaminase (AST), alanine transaminase (ALT), 
and alkaline phosphatase (ALP) were isolated by reagent kits 
in a stable liquid using enzymatic method. C-reactive protein 
(CRP) was measured by the quantitative method of CRP-
Latex immunoturbidimetric Assay (CRP-LIA). To measure 
insulin and HbA1c, Bio-Rad and NycoCard™ HbA1c kits 
were used, respectively. The level of low density lipoprotein 
(LDL) cholesterol was calculated by Friedewald formula. 
The level of insulin-resistance was also measured based on 
HOMA-IR formula as follows: FBS (mg/dL) x serum insulin 
/ 405. Blood pressure was recorded by a trained nurse using 
a mercury manometer, after 5-min resting at sitting position.  
Side effects and reports: During the study, the subjects 
were checked by the study expert every two weeks to 
monitor treatment and possible side effects through telephone 
call. Also, to report any side effects out of the mentioned 
time interval, the telephone number of the expert was given 
to the subjects. Note that at the beginning and end of the 
study, kidney and liver function tests were also performed. 
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Ethical considerations: The produced medicine was 
certified by Iranian Food and Drug Administration, and 
Ministry of Health and Medical Education (No. 85-026-s-t). 
The study protocol was provided based on Helsinki 
declaration on ethical principles and approved in the 
Research Ethics Committee of Qom University of Medical 
Sciences, Qom, Iran (ir.muq.rec.1395.42). The study was 
also designed based on customary, ethical, and religious 
norms of the associated community and data confidentiality 
was carefully followed by the study authors. The medicine 
and its probable side effects were thoroughly explained by a 
physician to the subjects. Written informed consent was 
obtained from all subjects. The subjects were free to 
withdraw from the study at any time they desired. Also, all 
laboratory tests and medicines were free of charge for the 
subjects. The study was registered in the Iranian Registry of 
Clinical Trials (IRCT2016011826097N1). 
Study analysis: To analyze the qualitative variables, 
frequency and the percentage of frequency, and to analyze 
the quantitative variables, the mean and standard error of the 
mean (SEM).were measured, based on the collected data. To 
analyze quantitative variables further, the independent t-test, 
was used, and to measure parameter changes in the group, 
the paired samples t-test was employed. To analyze the 
qualitative variables further, the Mc Nemar Chi-square test 
was used. The impact of multivariate effects of the medicine 
was analyzed by covariance analysis. A P<0.05 was 
considered significant.  
 
 
Results  
In the current study, two groups of 38 subjects (the case 
and control) were evaluated. The subjects were followed up 
every two weeks by telephone call and every six weeks 
through physical examination (the study duration was 12 
weeks). At the beginning of the study, three subjects did not 
refer to pharmacy for their medicines and were absent in 
follow-ups; one subject from the control group and two 
subjects from the case group. After 12 weeks of the study, 
five subjects were excluded from the study due to 
unwillingness and lack of cooperation with the study. No 
side effects and complications were reported from the 
subjects who consumed the medicine up to week 12. At the 
end of the study, three subjects (one from the case and two 
from the control groups) were excluded due to their 
willingness to use insulin. Out of 64 subjects, 33 subjects 
remained in the control and 31 in the case groups. There was 
no significant difference between the groups regarding the 
number of excluded subjects. According to the laboratory 
tests, there were no significant differences in the level of 
urea, creatinine, and amino transaminase enzymes between 
the groups.   
In the current study, 64 subjects were evaluated, 
including 16 (25%) males and 48 (75%) females, out of 
whom 33 (8 males and 25 females) subjects were in the case 
group and 31 (8 males and 23 females) were in the control 
group. The difference between the groups regarding the 
number of subjects was insignificant (P=0.8).  
The demographic information and medical data of the 
subjects at the beginning of the study are reported in table 1. 
 
Table 1. The Information of subjects in both groups, 
before the intervention 
Groups  Control  
(Mean±SEM) 
Case 
(Mean±SEM) 
P-
value 
Age  56.9±1.48 56.51±1.47 0.840 
Weight  77.24±2.53 76.58±1.84 0.836 
Disease duration 
(year) 
11.57±0.89 12.12±0.96 0.67 
Systolic blood 
pressure 
130.90±2.49 127.90±2.67 0.414 
Diastolic blood 
pressure  
84.24±1.32 82.41±1.08 0.295 
2hppBG 291.45±16.43 318.12±14.08 0.225 
FBS 192.72±14.37 210.61±9.29 0.307 
HbA1c 9.26±0.34 9.72±0.33 0.346 
Urea 31.00±1.45 30.00±1.62 0.650 
Creatinine 0.92±0.02 0.98±0.02 0.201 
Triglyceride 194.09±13.88 176.90±15.05 0.404 
Cholesterol 195.18±6.24 187.00±6.87 0.381 
LDL cholesterol 104.33±4.21 109.87±11.49 0.645 
HDL cholesterol 45.27±1.81 45.12±1.72 0.954 
SGOT 17.15±1.59 18.58±1.12 0.471 
SGPT 21.03±2.32 24.22±2.37 0.340 
ALP 119.18±13.20 129.58±10.59 0.544 
CRP 2.21±0.35 2.29±0.36 0.888 
HOMA-IR 3.3±2.1 4.1±1.9 0.1 
2hppBS: 2-Hour Post-Prandial Blood Glucose; FBS: Fasting Blood 
Sugar; HbA1C: Glycated Hemoglobin A1c; LDL: Low-Density 
Lipoprotein; HDL: High-Density Lipoprotein; SGOT: Aspartate 
Transaminase; SGPT: Alanine Transaminase; ALP: Alkaline 
Phosphatase; CRP: C-Reactive Protein 
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According to table 1, there was no significant difference 
between the groups regarding the evaluated parameters. 
Based on table 2, consuming the medicine significantly 
reduced the level of FBS from 210.61±9.29 to 178.25±5.50 
mg/dL. Also, the use of medicine significantly lowered the 
level of 2hpp BS (P=0.002). In addition, according to table 2, 
the use of medicine significantly reduced the level of HbA1c 
(P=0.0001). The level of glucose improved in the subjects 
through reducing insulin resistance; the level of insulin 
resistance diminished from 1.9±4.1 to 1.4±2.6 by consuming 
the medicine (P=0.001).  
However, the medicine had no effect on blood pressure 
and lipid profile values. The subjects’ data were collected 
after consuming the placebo and accordingly, no significant 
difference was observed on the evaluated parameters  
(table 2). 
 
Table 2. The information of subjects in the case and control groups, before and after intervention 
 Control group  Case group  
 Before 
(Mean±SEM) 
After 
(Mean±SEM) 
p-value Before 
(Mean±SEM) 
After 
(Mean±SEM) 
P-value 
Systolic blood pressure 130.90±2.49 129.09±2.45 0.61 127.90±2.67 124.06±2.77 0.68 
Diastolic blood pressure  84.24±1.32 77.58±1.17 0.82 82.41±1.08 77.58±1.17 0.89 
2hppBG 291.45±16.43 266.85±11.59 0.097 318.12±14.08 270.90±9.21 0.002 
FBS 192.72±14.37 178.96±8.45 0.328 210.61±9.29 178.25±5.50 0.0001 
HbA1c 9.26±0.34 8.66±0.28 0.078 9.72±0.33 8.39±0.20 0.0001 
Urea 31.00±1.45 29.92±1.82 0.56 30.00±1.62 26.74±1.07 0.6 
Creatinine 0.92±0.02 0.96±0.02 0.53 0.98±0.02 0.90±0.03 0.58 
Triglyceride 194.09±13.88 212.48±15.53 0.168 176.90±15.05 213.38±16.79 0.078 
Cholesterol 195.18±6.24 194.63±7.35 0.941 187.00±6.87 193.22±5.13 0.419 
LDL cholesterol 104.33±4.21 112.93±3.59 0.126 109.87±11.49 128.90±9.54 0.270 
HDL cholesterol 45.27±1.81 45.03±1.46 0.909 45.12±1.72 44.64±1.73 0.797 
SGOT 17.15±1.59 20.51±1.02 0.68 18.58±1.12 21.38±1.35 0.70 
SGPT 21.03±2.32 22.12±1.42 0.65 24.22±2.37 23.70±2.52 0.76 
ALP 119.18±13.20 161.30±12.28 0.81 129.58±10.59 156.29±7.93 0.78 
CRP 2.21±0.35 2.79±0.38 0.270 2.29±0.36 2.81±0.30 0.231 
HOMA-IR 3.3±2.1 3.2±2 0.6 4.1±1.9 2.6±1.4 0.001 
2hppBS: 2-Hour post-prandial blood glucose; FBS: fasting blood sugar; HbA1C: glycated hemoglobin A1c; LDL: low-density lipoprotein; HDL: high-density 
lipoprotein; SGOT: aspartate transaminase; SGPT: alanine Transaminase; ALP: alkaline phosphatase; CRP: C-Reactive Protein 
 
Discussion 
Type 2 diabetes is a multifactorial disease associated 
with different complications such as obesity, 
hypertriglyceridemia, impaired glucose tolerance (IGT), and 
increased insulin resistance, imposing a heavy financial 
burden to the healthcare economy. Considering the high 
prevalence of this disease and the increasing tendency of 
people toward consuming herbal medicines, it is necessary to 
evaluate the effects of such medicines on controlling blood 
glucose and the associated side effects. Recent evaluations 
have suggested that more than 80% of people in developing  
countries use herbal medicines to treat different diseases (7). 
The current study evaluated the effectiveness of an herbal 
combination with no significant side effects on the control of  
 
blood glucose in a group of patients not eligible to receive 
OADs. Since there was no similar combination for the herbal 
medicine, its effects cannot be compared with the results of 
other studies. Therefore, every component of the medicine 
was evaluated individually. The herbal medicine used in the 
current study contained nettle leaf 20% (w/w), berry leaf 
10% (w/w), onion and garlic 20% (w/w), fenugreek seed 
20% (w/w), walnut leaf 20% (w/w), and cinnamon bark 10% 
(w/w), all in powder. Vengerovskii AI et al. (17) reported 
useful effects of nettle (100 mg/kg) on the control of blood 
glucose in diabetic rats. They also indicated triglyceride-
lowering effects for nettle at the same dose. Kianbakht S.et 
al. evaluated the effects of 500 mg nettle three capsules a day 
for three months and reported positive therapeutic effects 
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(18). According to their results, nettle has simulating effects 
on the secretion of insulin, peroxisome proliferator-activated 
receptor (PPAR)-gamma agonist, and the inhibitory effect on 
alpha-glucosidase. According to the results of the current 
study including elevated insulin and diminished 2hppBG and 
insulin resistance, the theory of Kianbakht S. et al. seems to 
be correct. Patel SSet al. studied the effect of essential oil of 
nettle leaf on diabetic rats and reported that this essential oil 
has the potential to reverse the diabetes risk factors through 
making changes in muscarinic cholinergic system in 
hippocampus and accordingly can improve memory function 
(19). According to the mentioned and other conducted 
studies (14), it seems that nettle is a useful component to 
treat type 2 diabetes. Fenugreek is another herbal component 
extensively used to control diabetes, but its efficiency in the 
control of blood glucose is still unknown. The active 
components of fenugreek are soluble fiber, 
saponin of Trigonella foenum-graecum, diosgenin, and 4-
hydroxyisoleucine (4-OH-Ile). The blood glucose controlling 
effects of fenugreek are generally attributed to increasing 
dietary fiber and saponin (20).  
Animal studies have indicated that the essential oil of 
fenugreek seed can decrease enzymatic digestion of 
carbohydrates, gastrointestinal absorption of glucose, and the 
level of 2hppBG (21). In addition, fenugreek can stimulate 
glucose absorption in peripheral tissues (22) and secretion of 
insulin in rats (23). However, according to the 
aforementioned results, the therapeutic effects of fenugreek 
are contradictory. Some long-term clinical trials have found 
that fenugreek can decrease the level of HbA1c, FBS, and 
2hppBG (24). According to these studies, it seems that the 
dose of consumption affects the response to the treatment, 
and most of the positive therapeutic findings were achieved 
following the use of higher doses of fenugreek seed powder 
(> 5 mg) (20). 
Cinnamon is another herb with benefits to control blood 
glucose, though the results have been contradictory. Some 
studies have indicated its effect on reducing blood glucose in 
patients with diabetes (25), while some others did not believe 
in such effects of cinnamon (26). Auto-phosphorylation and 
-dephosphorylation of insulin receptor, synthesis and transfer 
of glucose transporter 4 (GLUT-4), regulation of liver 
metabolism through making changes in pyruvate kinase (PK) 
and phospho enol pyruvate carboxylase (PEPC), and 
inhibition of intestinal glucosidase are some of the 
mechanisms proposed for the effectiveness of cinnamon on 
blood glucose (27). Hlebowicz et al. indicated the effect of 
cinnamon on reducing the gastric emptying rate (28). The 
negative effect of cinnamon on the level of blood urea and 
uric acid are the points that should be considered in its 
consumption (29). Nausea, skin rashes, hives, and even 
seizures following hypoglycemia have been reported 
following consumption of high doses of cinnamon (27). 
Garlic (Allium sativum) is an aromatic plant traditionally 
planted and used in different parts of Iran due to its aroma 
and healing properties. Although garlic have been under 
consumption for centuries and in many regions of the world, 
there is little information about its therapeutic effects. 
Although animal studies have reported the effect of garlic on 
reducing blood glucose in diabetic animals, the results in 
some studies have been contradictory (30). It should be 
noted that there are a few human studies on the blood 
glucose reducing effect of garlic (31) and the history of using 
garlic goes back to thousand years ago. Historically, a great 
deal of attention has been paid to the role of garlic in 
reducing cardiovascular risk factors. However, a few 
scientific data are available to support its therapeutic effects. 
Recently, the use of garlic to treat diabetes has increased and 
new information has been reported regarding its blood 
glucose and lipid-lowering as well as anti-arteriosclerosis 
effects (32).  
In a study, Rajupadiaet reported that garlic can improve 
insulin sensitivity, while, metabolic syndrome and oxidative 
stress reduced the amount of food in rats (33). The study by 
Jalal et al. entitled: “the blood glucose-lowering effect of 
shallot and garlic diluted extract”, reported that garlic and 
shallot extracts had blood-glucose lowering effects on rats in 
which insulin-resistance was induced by fructose. The 
shallot extract was more effective in this regard compared to 
garlic extract (34). In a study by Ebadi et al. entitled: 
“evaluating the effect of garlic tablet on blood glucose in 
patients with type 2 diabetes”, the results suggested that use 
of garlic tablets significantly reduced the level of FBG in the 
case group, compared to the control. Also, garlic 
significantly reduced the level of HbA1c (1.5%) in the case 
group compared to the control group, which was 0.2%. 
There was no significant reduction in the blood glucose of 
the control group. In the current study, garlic significantly 
reduced the level of FBS and HbA1c in the case group 
compared to the control group. Accordingly, it seems that it 
can be used as a significant agent to control and treat 
diabetes. 
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Walnut, Junglansregia, is another plant used in Iranian 
traditional medicine for its various therapeutic effects such 
as blood glucose-lowering properties. Walnut leaves include 
tannin, essential fatty acids, ascorbic acid, flavonoids, folic 
acid, and para-coumaric acid, in addition to naphthalene 
derivatives, especially 5-hydroxy-1, and 4-naphthoquinone 
(35). Juglone is the most abundant compound in different 
organs of walnut plant with C10H5O2 (OH) formula and 
174.16KDa molecular weight. The precursor of juglone, 
which hydrolysis to juglone, is a glycoside found in 
combination forms in aerial organs, especially leaves (36). 
Some previous studies suggested that the brewed walnut leaf 
and olive can significantly reduce the blood glucose in 
patients with diabetes (36).  
The effect of hydraulic extract of walnut leaves on 
healthy and diabetic rats was assessed in another study. It 
found that dose-dependent consumption of the extract 
reduced blood glucose in the diabetic rats, but had no effect 
on their healthy peers. Hence, the effect of such extract is 
comparable with that of some drugs such as metformin. The 
study by Hosseini et al. indicated that the level of FBS, 
HbA1c, total cholesterol, and triglyceride significantly 
decreased in the patients with diabetes under treatment with 
walnut, compared with the levels at the beginning of the 
study and those of the control group (38).  
Black mulberry, Morus nigra. grows on a tree with 4-10 
m height, and numerous and short branches. Leaves of black 
mulberry are dark green with a heart-shaped blade, and 
irregular and jagged divisions. The skin, root, leaf, and fruit 
of the tree are used in medicine. The extract of black 
mulberry leaves has many therapeutic effects such as anti-
hypertensive, diuretic, and hypoglycemic effects (39). 
Due to the type of drug and its effective amount, the size 
of the capsules was slightly big and it was difficult for some 
patients to swallow it. 
In conclusion according to the results of the current 
study, the herbal combination used in the study controlled 
blood glucose, and considering its HbA1c-lowering effect by 
1.31 %, it can be considered an effective medicine to treat 
diabetes. Since the patients with a history of using OADs as 
well as reduction of insulin-resistance following the 
consumption of the herbal medicine in the current study 
formed the population here, it is recommended to design a 
study on the early diagnosed cases to evaluate the 
effectiveness of the herbal combination in the initial 
treatment of diabetes.  
Acknowledgments 
The researchers thank the Booali Pharmaceutical 
Company for producing and supplying the drug required for 
this project and to the research deputy of Qom University of 
Medical Sciences and the department of clinical trial 
development. 
 
Funding: The present paper was based on an 
MD thesis from general practice by Maryam Rafiei and 
Zahra Hosseini. 
Conflicts of interest: The authors declare that they have no 
conflicts of interest concerning this manuscript. 
 
List of abbreviations used 
CAM: Complementary and alternative medicine; CIM: 
Complementary and Integrative Medicine; HbA1C:Glycated 
hemoglobin (hemoglobin A1c); CRP:C reactive protein; 
FBS: Fasting blood sugar;  2hppBS:2-hour Post-prandial 
blood sugar ;LDL: Low-density lipoprotein; HDL: High-
density lipoprotein; SGOT: Aspartate transaminase; SGPT: 
Alanine transaminase 
 
 
References 
1. Zimmet P. Globalization, coca-colonization and the 
chronic disease epidemic: can the Doomsday scenario be 
averted? J Intern Med 2000; 247: 301-10. 
2. Simpson RW, Shaw JE, Zimmet PZ. The prevention of 
type 2 diabetes lifestyle change or pharmacotherapy? A 
challenge for the 21st century. Diabetes Res Clin Pract 
2003; 59: 165-80. 
3. Morowatisharifabad MA, Rouhani Tonekaboni N. The 
relationship between perceived benefits/barriers of self-
care behaviors and self-management in diabetic patients. 
J Hayat 2007; 13: 17-27. 
4. Foster DW, Brawnwald E, Wilson D, et al. Harrison s 
principals of internal medicine, diabetes mellitus. 13th 
ed. USA: McGraw Hill 1994; pp: 1979-81.  
5. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic 
and molecular implications for identifying diabetes 
genes. Diabetes Rev 1997; 5: 177-269. 
6. Garrow D, Egede LE. Association between 
complementary and alternative medicine use, preventive 
care practices, and use of conventional medical services 
among adults with diabetes. Diabetes Care 2006; 29: 15-
9. 
 Caspian J Intern Med 2020; 11(1):12-20  
Effect of her on type 2 Diabetes                                                                      19 
7. Ranasinghe P, Jayawardena R, Galappathy P, et al. 
Efficacy and safety of ‘true’ cinnamon 
(Cinnamomumzeylanicum) as a pharmaceutical agent in 
diabetes: a systematic review and meta-analysis. Diabet 
Med 2012; 29: 1480-92. 
8. Bell RA, Suerken CK, Grzywacz JG, et al. 
Complimentary and alternative medicine use among 
adults with diabetes in the United Sates. Altern Ther 
Health Med 2006; 12: 16-22. 
9. Herman PM. Evaluating the economics of complementary 
and integrative medicine. Glob Adv Health Med 2013; 2: 
56-63. 
10. Kianbakht S, Khalighi-Sigaroodi F, Dabaghian FH. 
Improved glycemic control in patients with advanced 
type 2 diabetes mellitus taking Urtica dioica leaf extract: 
a randomized double-blind placebo-controlled clinical 
trial. Clin Lab 2013;59: 1071-6.  
11. Rajarajeswari A, Vijayalakshmi P, Sadiq AM. Influence 
of trigonella foenum graecum (fenugreek) in alloxan 
induced diabetic rats. Bioscan 2012; 7: 395-400. 
12. Moorthy R, Prabhu KM, Murthy PS. Mechanism of anti-
diabetic action, efficacy and safety profile of GII purified 
from fenugreek (Trigonella foenum-graceum Linn.) 
seeds in diabetic animals. Indian J Exp Biol 2010; 48: 
1119-22. 
13. Divband K, Komeili GR, Saeidi-Neek F. Effects of 
Walnut leaves aqueous extract on blood sugar and serum 
lipids in diabetic rats. J Birjand Univ Med Sci 2010; 17: 
11-18.  
14. Mohamed Sham Shihabudeen H, Hansi Priscilla D, 
Thirumurugan K. Cinnamon extract inhibits a-
glucosidase activity and dampens postprandial glucose 
excursion in diabetic rats. Nutr Metab 2011; 8: 46. 
15. Golalipour MJ, Ghafari S, Kouri V, Keshtkar AA. 
Proliferation of the β-Cells of pancreas in diabetic rats 
treated with urtica dioica. Int J Morphol 2010; 28: 399-
404. 
16. Amiri Behzadi A, Kalalian-Moghaddam H, Ahmadi AH. 
Effects of Urtica dioica supplementation on blood lipids, 
hepatic enzymes, and nitric oxide levels in type 2 
diabetic patients: A double blind, randomized clinical 
trial. Avicenna J Phytomed 2016; 6: 686-95. 
17. Vengerovskii AI, Yakimova TV, Nasanova ON. 
Influence of medicinal plant extracts on the functions and 
antioxidant protection of erythrocytes in rats with 
experimental diabetes mellitus. Eksp Klin Farmakol 
2016; 79: 29-33. 
18. Kianbakht S, Khalighi-Sigaroodi F, Dabaghian FH. 
Improved glycemic control in patients with advanced 
type 2 diabetes mellitus taking Urticadioica leaf extract: a 
randomized double-blind placebo-controlled clinical trial. 
Clin Lab 2013; 59: 1071-6. 
19. Patel SS, Parashar A, Udayabanu M. Urticadioica leaves 
modulates muscarinic cholinergic system in the 
hippocampus of streptozotocin-induced diabetic mice. 
Metab Brain Dis 2015; 30: 803-11. 
20. Neelakantan N, Narayanan Mde Souza RJ, van Dam RM. 
Effect of fenugreek (Trigonellafoenum-graecumL.) 
intake on glycemia: a meta-analysis of clinical trials. 
Nutr J 2014; 13: 7. 
21. Hannan JM, Ali L, Rokeya B, et al. Soluble dietary fibre 
fraction of Trigonellafoenum-graecum (fenugreek) seed 
improves glucose homeostasis in animal models of type 1 
and type 2 diabetes by delaying carbohydrate digestion 
and absorption, and enhancing insulin action. Br J Nutr 
2007, 97: 514-21. 
22. Vijayakumar MV, Singh S, Chhipa RR, Bhat MK. The 
hypoglycaemic activity of fenugreek seed extract is 
mediated through the stimulation of an insulin signaling 
pathway. Br J Pharmacol 2005; 146: 41-8. 
23. Broca C, Manteghetti M, Gross R, et al. 4-
Hydroxyisoleucine: effects of synthetic and natural 
analogueson insulin secretion. Eur J Pharmacol 2000; 
390: 339-45. 
24. Rafraf M, Malekiyan M, Asghari-Jafarabadi M, 
Aliasgarzadeh A. Effect of fenugreek seeds on serum 
metabolic factors and adiponectin levels in type 2 
diabetic patients. Int J Vitam Nutr Res 2014; 84: 196-
205. 
25. Crawford P. Effectiveness of cinnamon for lowering 
hemoglobin A1C in patients with type 2 diabetes: a 
randomized, controlled trial. J Am Board Fam Med 2009; 
22: 507-12. 
26. Vanschoonbeek K, Thomassen BJ, Senden JM, Wodzig 
WK, van Loon LJ. Cinnamon supplementation does not 
improve glycemic control in postmenopausal type 2 
diabetes patients. J Nutr 2006; 136: 977-80. 
27. Medagama AB. The glycaemic outcomes of Cinnamon, 
areview of the experimental evidence andclinical trials. 
Nutr J 2015: 14: 108. 
 Caspian J Intern Med 2020; 11(1):12-20 
20                                                                             Parham M, et al. 
28. Hlebowicz J, Darwiche G, Bjorgell O, Almer LO. Effect 
of cinnamon on post prandial blood glucose, gastric 
emptying and and satiety in healthy subjects. Am J Clin 
Nutr 2007; 85: 969-76. 
29. Al-Logmani AS, Zari TA. Effects of Nigella sativa L. 
and Cinnamomum zeylanicum Blume oils on some 
physiological parameters in streptozotocin-induced 
diabetic rats. Boletín latinoamericano Y Del Caribe De 
Plantas Medicinales Y Aromáticas 2009; 8: 86-96.  
30. Liu CT, Wong PL, Lii CK, Hse H, Sheen LY. 
Antidiabetic effect of garlic oil but not diallyldisulfidein 
rats with streptozotocin-induced diabetes. Food Chem 
Toxicol 2006, 44: 1377-84. 
31. Zhang XH, Lowe D, Giles P, et al. Gender may affect the 
action of garlic oil on plasma cholesterol and glucose 
levels of normal subjects. J Nutr 2001; 131: 1471-8. 
32. Wang HX, Ng TB. Natural products with hypoglycemic, 
hypotensive, hypocholesterolemic, antiatherosclerotic 
and antithrombotic activities. Life Sci 1999; 65: 2663-77. 
33. Padiya R, Khatua TN, Bagul PK, Kuncha M, Banerjee 
SK. Garlic improves insulin sensitivity and associated 
metabolic syndromes in fructose fed rats. Nutr Metab 
2011; 8: 53. 
34. Jalal R, Bagheri SM, Moghimi A, Rasuli MB. 
Hypoglycemic effect of aqueous shallot and garlic 
extracts in rats with fructose-induced insulin resistance. J 
Clin Biochem Nutr 2007; 41: 218-23.  
35. Lacy PE, Finke EH, Conant S, Naber S. Long-term 
perifusion of isolated rat islets in vitro. Diabetes 1976; 
25: 484-93. 
36. Kamkar J, Rezaei MB, Baghaei P, Sajadipoor SA, 
Nasrabadi M. Determination of juglone from leaves and 
fresh peels of Juglansregia L. by high performance liquid 
chromatography. Iran J Med Aromatic Plants 2004; 20: 
323-31. [in Persian] 
37. Zargari A. Medicinal Plants. 6th ed. Tehran: Tehran 
University Publication 1997; pp: 249-65. [in Persian] 
38. Hosseini S, Jamshidi L, Mehrzadi S, et al. Effects of 
Juglans regia L. leaf extract on hyperglycemia and lipid 
profiles in type two diabetic patients: a randomized 
double-blind, placebo-controlled clinical trial. J 
Ethnopharmacol 2014; 152: 451-6. 
39. Kim JY, Ok HM, Kim J, et al. Mulberry leaf extract 
improves postprandial glucose response in prediabetic 
subjects: a randomized, double-blind placebo-controlled 
trial. J Med Food 2015; 18: 306-13. 
 
 
 
 
